All lobbying filings

THE MCMANUS GROUP

Lobbying for GENENTECH

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jul 21, 2025

Official filing document

Bills named in this filing 1

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Lobbying activity 3

Medicare/Medicaid

Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model

Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.

Taxation/Internal Revenue Code

Issues related to tax exempt hospitals and charity care. Issues related to corporate tax reform.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.